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Background: Empirical studies investigating the prevalence of mental disorders and psychological distress in
cancer patients have gained increasing importance during recent years, particularly with the objective to develop
and implement psychosocial interventions within the cancer care system. Primary purpose of this epidemiological
cross-sectional multi-center study is to detect the 4-week-, 12-month-, and lifetime prevalence rates of comorbid
mental disorders and to further assess psychological distress and psychosocial support needs in cancer patients
across all major tumor entities within the in- and outpatient oncological health care and rehabilitation settings
in Germany.
Methods/Design: In this multicenter, epidemiological cross-sectional study, cancer patients across all major tumor
entities will be enrolled from acute care hospitals, outpatient cancer care facilities, and rehabilitation centers in five
major study centers in Germany: Freiburg, Hamburg, Heidelberg, Leipzig and Würzburg. A proportional stratified
random sample based on the nationwide incidence of all cancer diagnoses in Germany is used. Patients are
consecutively recruited in all centers. On the basis of a depression screener (PHQ-9) 50% of the participants that
score below the cutoff point of 9 and all patients scoring above are assessed using the Composite International
Diagnostic Interview for Oncology (CIDI-O). In addition, all patients complete validated questionnaires measuring
emotional distress, information and psychosocial support needs as well as quality of life.
Discussion: Epidemiological data on the prevalence of mental disorders and distress provide detailed and valid
information for the estimation of the demands for the type and extent of psychosocial support interventions. The
data will provide information about specific demographic, functional, cancer- and treatment-related risk factors for
mental comorbidity and psychosocial distress, specific supportive care needs and use of psychosocial
support offers.Background
Cancer is one of the leading causes of morbidity and
mortality worldwide [1,2]. An estimated 3.2 million new
cancer cases were diagnosed in Europe in 2008 [1]. The
most frequent forms of cancer were colorectal cancers
(13.6% of all cancer cases), breast cancer (13.1%), lung
cancer (12.2%) and prostate cancer (11.9%). In Germany,* Correspondence: mehnert@uke.de
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reproduction in any medium, provided the orrecent epidemiological estimates indicate a projected an-
nual incidence rate for 2010 of about 450,000 cancer
cases [3]. Cancer incidence statistics show an enhanced
5-year survival rate up to 62% for women and 57% for
men, including all cancer stages. The average age of
onset of cancer is 69 years for both genders. For the
population of 82 million people in Germany, these
developments lead to a prevalence of 1.4 million cancer
patients within the range of five years post diagnosis and
2.1 million cancer patients in whom the diagnosis is
back up to 10 years [3].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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advances in cancer detection, multimodal treatments
and targeted therapies, the proportion of cancer sur-
vivors continues to grow in industrialized countries.
Cancer survivorship covers a variety of medical condi-
tions and periods that are divided into acute survival,
middle and long-term survival including disease-free
survival as well as cancer recurrence and chronic disease
[4]. Thus, short, middle and long-term survivorship
has significant implications for both clinical and psy-
chosocial research as well as for health care services
research [5-7].
Comprehensive patient-centered care in oncology has
been emphasized in international guidelines and stan-
dards [8], implying cancer prevention and early detec-
tion as well as high quality evidence-based medical
treatment, rehabilitation and palliative care. Improving
the quality of care requires recognition and addressing
patients’ distress, mental disorders and supportive care
needs during treatment and after care. Thus, psycho-
social and psycho-oncological support services consider-
ably contribute to improving the quality of life of
patients as a central outcome criterion of oncological
care [9].
Emotional distress is common after a cancer diagnosis
[10], and is often a result of a variety of problems that
can affect every aspect of life according to different
stages of the disease. Typical issues relate to physical
symptoms and problems such as pain, functional impair-
ments and states of chronic fatigue, family burden such
as the uncertainty about individual roles and responsibil-
ities, existential concerns such as isolation or meaning in
one's life as well as social, financial and occupational
problems [11].
Many cancer patients suffer from a high symptom bur-
den, which can remain for months and years after the
initial cancer therapy or can occur again in the face of
long-term therapy or complications in the disease tra-
jectory. High symptom burden is associated with a
significant increase in feelings of helplessness and hope-
lessness and may adversely impact a patient’s quality of
life [12-14]. The spectrum of emotional reactions and
psychosocial consequences ranges along a continuum
including anxiety, fear, sadness and depression, helpless-
ness and hopelessness as well as adjustment disorders,
anxiety disorders, posttraumatic stress disorder, depres-
sion, family conflicts or existential crises [11,15-17].
Empirical studies investigating the prevalence of men-
tal disorders and the frequency of psychosocial burden
in cancer patients have gained increasing importance
during recent years [18]. This research is of particular
significance for the development and implementation of
psychosocial support offers within the health care sys-
tem. Recent meta-analytical evidence indicates that theoverall prevalence of mental disorders among cancer
patients ranges from 9.8% to 38.2% in various cancer set-
tings [19,20]. In an international review conducted by
Mitchell et al. [19] including 94 interview-based studies,
the prevalence of depression by DSM or ICD criteria in
oncological and hematological settings (70 studies) was
16.3% (95% CI 13.4–19.5); the prevalence of dysthymia
was 2.7% (95% CI 1.7–4.0); the prevalence of adjustment
disorder was 19.4% (95% CI 114.5–24.8); and the preva-
lence of anxiety disorders was 10.3% (95% CI 5.1–17.0).
However, combination diagnoses were prevalent among
up to 38.2% (95% CI 28.4–48.6) of patients. The preva-
lence of depression by DSM or ICD criteria in palliative-
care settings (24 studies) was 16.5% (95% CI 13.1–20.3);
the prevalence of adjustment disorder was 15.4% (95%
CI 10.1–21.6); the prevalence of anxiety disorders was
9.8% (95% CI 6.8–13.2); and combination diagnoses were
prevalent among up 29.0% (95% CI 10.1–52.9) of
patients. Accordingly, Singer et al. [20] observed preva-
lence rates up to 32% (95% CI 27–37) among cancer
patients in acute hospitals.
However, few trials have examined the prevalence of
mental disorders in cancer patients taking into account
the wide spectrum of mental disorders including sub-
stance abuse or somatoform disorders, different health
care settings as well as different tumor entities and dis-
ease stages for both genders. Fewer studies have exam-
ined the 4-week-, 12-month-, and lifetime prevalence
rates of comorbid mental disorders in cancer patients
[21] and the association between comorbid mental disor-
ders and psychological distress.
The presence of a mental disorder or psychological
symptom burden is not necessarily associated with sub-
jective needs of patients for professional psychosocial
support and the utilization of relevant offers [22].
Although a variety of psychological interventions have
been shown to be effective in the reduction of psy-
chosocial symptom distress and the improvement of
quality of life [23-25], however, improving distress
screening and the access of cancer patients to ade-
quate psychosocial care remains a critical concern [26].
Thus epidemiological data about mental comorbidity,
psychological symptom burden and supportive care
needs are essential for the evidence based implementa-
tion of psychosocial support offers within oncological
health care.
Objectives
Although there has been extensive research looking at
emotional distress among various cancer entities, there
is limited evidence regarding prevalence rates of comor-
bid mental disorders in cancer patients across different
tumor entities and care settings from an epidemiological
point of view. Main research aim of this epidemiological
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week-, 12-month-, and lifetime prevalence rates of
comorbid mental disorders according to the ICD-10
/DSM-IV (organic, including symptomatic, mental dis-
orders, mental and behavioral disorders due to psy-
choactive substance use, mood disorders, neurotic,
stress-related and somatoform disorders, and behavioral
syndromes associated with physiological disturbances
and physical factors); and to further assess psychological
distress and psychosocial supportive care needs in
cancer patients across all major tumor entities within
the in- and outpatient oncological health care and
rehabilitation settings in Germany.
Secondary aims are to examine the impact of demo-
graphic, functional, cancer- and treatment-related risk
factors on the occurrence of mental comorbidity, psy-
chosocial distress, specific supportive care needs and use
of psychosocial support offers. Associations between
mental comorbidity, psychosocial distress, supportive
care needs, quality of life and medial decision-making
will be also examined.
Methods/Design
Study design
In this multicenter, epidemiological cross-sectional
study, cancer patients will be enrolled from acute care
hospitals, outpatient cancer care facilities, cancer re-
habilitation centers and clinics in five major study cen-
ters in Germany (Freiburg, Hamburg, Heidelberg,
Leipzig and Würzburg). The centers are selected to rep-
resent various typical regions in Germany. Factors con-
sidered are the geographic location including new and
old federal states, cities and towns, and different cancer
care facilities. In each study center and surrounding
areas, the university medical center, another hospital
offering maximum medical care, three to four outpatient
care facilities providing basic medical care and those
serving as regional cancer centres as well as a minimum
of two rehabilitation clinics are included for data collec-
tion. Patients are consecutively recruited in all centers.
Figure 1 gives an overview over the research design.
Study participants
Patient inclusion criteria contain the evidence of a ma-
lignant tumor and age between 18 through 75 years due
to the validity of the Composite International Diagnostic
Interview (M-CIDI) [27] which was adapted for cancer
patients (CIDI-O). The oncology-specific adaption of the
CIDI-O enhances the diagnostic spectrum of the M-
CIDI by adding the diagnostic group of stress-related
mental disorders, particularly due to cancer disease. A
prominent modification strategy that fostered the devel-
opment of the CIDI-O is the adding-on of cancer-
related questions in the interview sections for depressivedisorders, anxiety disorders and PTSD assessing differ-
ent types of stressors and specifying time association of
mental symptoms and stressors. Patients across all
tumor entities and disease stages are included stratified
by nationwide incidence of cancer diagnoses (see sample
stratification). Patient exclusion criteria contain the pres-
ence of severe physical, cognitive and/or verbal impair-
ments that would interfere with a patient’s ability to give
informed consent for research.
Recruitment and data collection
The study received research ethics committee approval
in all involved federal states (The study was approved by
the following Medical Associations: Hamburg: Ref. Nr.
2768, Schleswig-Holstein: Ref.-Nr. 61/09; Freiburg: Ref.-
Nr. 244/07, Heidelberg: Ref.-Nr. S-228/2007; 50155039;
Würzburg: Ref. Nr. 107/07; Leipzig: Ref. Nr. 200–2007).
All patients who fulfill the study inclusion criteria are
contacted by study staff and consecutively recruited at
the oncological health care settings and institutions in
all centers. All patients provide written informed con-
sent prior to participation. Principles of good research
practice are strictly adhered to in this project including
data and patient’s privacy protection.
Interviewer training and quality standards
The study center Hamburg is responsible for the coord-
ination of the data collection also ensuring the accuracy
of the assessment and the data input. Study interviewers
were trained extensively in a 1-2-day workshop on the
use of the computer-based CIDI-O. After training, each
interviewer conducted several test interviews of which
one interview was videotaped and evaluated by one
study center responsible for the quality assurance (Frei-
burg). Evaluation criteria included correct implementa-
tion of the interview questions, correctness of the
patient information as well as interactional factors. Each
interviewer received a detailed feedback on the imple-
mentation of the interviews. In addition, all conducted
patient interviews were evaluated by the study center
Freiburg. Incorrect interviews were excluded from the
record.
Randomization
All patients that score at the cutoff point of 9 or above
at the PHQ-9 (total score) [28] are interviewed (CIDI-
O), and 50% of the participants that score below this
cutoff point are randomized to CIDI-O interviews. Block
randomization is used in each center by each interviewer
to allocate participants to CIDI-O interviews. Block size
is defined by 20. Randomization is managed by using a
computer-based randomization program. At the mo-
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Figure 1 Overview over the research design.
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to obtain the assignment.Study measures
Table 1 gives an overview over the study measures.Demographics, medical history and functional performance
Sociodemographic information is collected through use
of a standardized self-report questionnaire (age, gender,
marital status and partnership, children, school education,Table 1 Overview over study measures
Screening measure: Patient Health Questionnaire (PHQ-9)
Standardized psychiatric interview
Composite International Diagnostic Interview for Oncology (CIDI-O)
Demographics, medical history and functional performance
Demographic characteristics
Medical characteristics
Karnofsky performance status scale
ECOG Scale
Brief Pain Inventory (BPI)
Emotional distress and quality of life
General Anxiety Disorder-Scale (GAD-7)
Hospital Anxiety and Depression Scale – German version (HADS)
NCCN Distress Thermometer
EORTC Quality of Life Questionnaire (EORTC QLQ – C30)
Psychosocial support and patient participation
Illness-specific Social Support Scale Short Version-8 (ISSS-8)
The Shared Decision Making Questionnaire (SDM-Q-9)
Control preference scale (CPS)
Information and supportive care needs and use of psychosocial supportvocational training, monthly household income, employ-
ment status and occupational situation).
Medical information regarding tumor entity, date of
and time since first and recurrent diagnosis, UICC dis-
ease stage, information about remission, cancer recur-
rence and progress, metastasis, curative or palliative
treatment intention, past and current cancer treatments
received as well as comorbid disorders is gathered
through medical records.
The Karnofsky performance status scale [29] is a
widely used performance measure for rating the abilityParticipants
PHQ-9: < 9 PHQ-9: ≥ 9
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evaluating a patient's progress after a therapeutic pro-
cedure, and determining a patient's suitability for ther-
apy. The lower the Karnofsky score, the worse the
survival for most serious illnesses such as cancer. A per-
son is evaluated on a score ranging from 0 to 100, where
0 is “dead” and 100 is “normal, no complaints, and no
signs of disease”.
The ECOG Scale [30,31] is used in addition to assess
how a patient's disease is progressing, and to assess how
the disease affects the daily living abilities of the patient.
A person is evaluated on a score ranging from 0 to 5,
where 0 is “fully active, able to carry on all pre-disease
performance without restriction” and 5 is “dead”.
Composite international diagnostic interview for oncology
(CIDI-O)
The M-CIDI was developed by the World Health
Organization (WHO) in collaboration with the US Alco-
hol, Drug Abuse, and Mental Health Administration
(ADAMHA) and translated into German language on
behalf of WHO [27]. As a key objective of this study, the
Composite International Diagnostic Interview for Oncol-
ogy (CIDI-O) was adapted for oncology patients based
on the Composite International Diagnostic Interview
(M-CIDI) in the DIA-X version. The CIDI-O is a stan-
dardized computer-based interview which enables the
diagnosis of mental disorders according to the ICD-10
and DSM-IV in a reliable, valid and efficient manner.
The following mental disorders are included: organic, in-
cluding symptomatic, mental disorders (F00-F09), men-
tal and behavioral disorders due to psychoactive
substance use (F10-F19), mood (affective) disorders
(F30-F39), neurotic, stress-related and somatoform dis-
orders (F40-F48) and behavioural syndromes associated
with physiological disturbances and physical factors
(F50-F59).
To compare the specific psychometric properties (e.g.
sensitivity and specificity) of screening measure for anx-
iety and depression in cancer populations, the HADS as
well as the PHQ-9 and the GAD-7 are used.
Patient health questionnaire (PHQ-9)
Depression is measured through use of the PHQ-9 Ger-
man version, the depression module of the Patient
Health Questionnaire [28,32]. The PHQ-9 is based on
the DSM-IV diagnostic criteria for major depressive dis-
order and has excellent reliability, as well as criterion,
construct, factorial, and procedural validity. The 9 items
assess the frequency of depressive symptoms within the
past two weeks. Items are scored on a four-point Likert
scale rated from 0 (not at all) to 3 (nearly every day)
with a total score ranging from 0 to 27. A cutoff point of
>9 is recommended for the screening of any depressivedisorder including adjustment disorder with depressed
mood with a sensitivity of 87% (95% CI 79–92) and a
specificity of 76% (95% CI 72–80) [33]. In addition to
the sum score for measuring depression severity, the
PHQ-9 offers a categorical algorithm based on modified
criteria of ‘major depressive disorder’, according to
DSM-IV. A score up to 4 indicates the absence of de-
pression, scores of 5–9 represent mild, scores of 10–14
represent moderate and scores of 15 and higher repre-
sent severe depression [33].
General anxiety disorder-scale (GAD-7)
The GAD-7 German version [34,35] is used to identify
probable cases of generalized anxiety disorder and to as-
sess symptom severity. The GAD-7 is based on the most
prominent diagnostic features of the DSM-IV diagnostic
criteria for generalized anxiety disorder and has excellent
reliability, as well as criterion, construct, factorial, and
procedural validity. The 7 items assess the frequency of
core symptoms of generalized anxiety disorder within
the past two weeks. Items are scored on a four-point
Likert scale rated from 0 (not at all) to 3 (nearly every
day) with a total score ranging from 0 to 21. A score up
to 4 indicates the absence of generalized anxiety dis-
order, scores of 5–9 represent mild, scores of 10–14 rep-
resent moderate and scores of 15 and higher represent
severe anxiety symptom levels [35].
Hospital anxiety and depression scale – German version
(HADS)
The HADS is a validated screening instrument for anx-
iety and depression in somatically ill patients [36] and
excludes symptoms that may arise from somatic aspects
of illness (e.g. insomnia, weight loss and fatigue). The
measure consists of 14 items on a 4-point Likert scale
(range 0–3) comprising an anxiety and depression sub-
scale. For both subscales a total score is calculated (ran-
ging from 0–21). A score of 0–7 is categorized as
normal, a score of 8 to 10 is considered to indicate a
possible anxiety or depressive disorder, and a score of 11
or above is considered to indicate a probable anxiety or
depressive disorder.
NCCN distress thermometer
The Distress Thermometer is a valid and reliable meas-
ure for screening psychological distress in patients with
cancer. Initially developed by the National Comprehen-
sive Cancer Network (NCCN) [37] the German version
was adapted by Mehnert et al. [38]. The measure con-
tains a single-item visual analogue scale ranging from 0
(“no distress”) and 10 (“extreme distress”) to quantify
global level of distress and a standardized symptom
checklist. The checklist consists of 36 potential causes of
distress (answered ‘yes’ or ‘no’) that are grouped into five
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tional problems, spiritual concerns and physical pro-
blems). A score of 5 or higher at the visual analogue
scale is recommended as a cutoff score for a clinically
significant level of distress.
Brief pain inventory (BPI)
Pain is assessed on the basis of the Brief Pain Inventory
(BPI) [39]. The BPI is a measure developed to assess
pain history, pain intensity, and pain interference with a
variety of activities. The BPI is well validated among can-
cer and chronic disease pain patients. In this study, only
pain intensity will be analyzed. Pain intensity during the
last week is evaluated on a scale ranging from 0 (‘no
pain’) to 10 (‘worst pain imaginable’).
European organization for research and treatment of
cancer quality of life questionnaire (EORTC QLQ – C30)
The EORTC Quality of Life Core Questionnaire
EORTC-QLQ-C30 [40] is used to measure cancer-
related QOL. The measure incorporates five functional
scales (physical, role, cognitive, emotional, social), three
symptom scales (pain, fatigue, nausea/vomiting), a global
health and quality-of-life scale, and several single items
for the assessment of additional symptoms commonly
reported by cancer patients (e.g. appetite loss, sleep dis-
turbance) as well as the perceived financial impact of the
disease and treatment. The EORTC QLQ – C30 consists
of 30 items that are scored on 4-point Likert scales, ran-
ging from 1 (“not at all”) to 4 (“very much”). Two items
in the global health and quality-of-life sub-scale are
scored on a 7-point linear analogue scale. All functional
scales and individual item scores are transformed to a
0–100 scale. Higher scores in the five functional scales
and global health status scale represent better function-
ing, whereas higher scores in symptom scales reflect a
greater extent of symptom distress.
Illness-specific social support scale short version-8 (ISSS-8)
The Illness-specific Social Support Scale (ISSS) was ori-
ginally developed by Revenson and Schiaffino [41], and
has been adapted to the German language by Ramm and
Hasenbring [42]. The newly developed 8-item validated
German version [43] of the ISSS measures positive sup-
port (4 items) and detrimental interaction (4 items). The
two scales ‘positive support’ and ‘detrimental interaction’
show internal consistencies with Cronbach’s alpha = .88
and .68. Items are scored on a 5-point Likert scale ran-
ging from 0 (‘never‘) to 4 (‘always‘).
The shared decision making questionnaire (SDM-Q-9)
The 9-item Shared Decision Making Questionnaire
(SDM-Q-9) [44] is a brief questionnaire developed to as-
sess the extent of patients’ participation in shareddecision making in the medical encounter. The present
revised version of the measure consists of nine items
developed on the basis of the nine process elements
characterizing shared decision making, ranging from the
disclosure that a decision needs to be made to a shared
decision and arrangements of follow up. In the study
version, items are scored on a 5-point Likert scale, ran-
ging from 0 (“strongly disagree”) to 4 (“strongly agree”).
Therefore, the SDM-Q-9 score can range from 0 to 36;
it is transformed to a 0–100 scale with higher values in-
dicating a higher extent of patients’ participation in
shared decision making.Control preference scale (CPS)
The Control preference scale (CPS) [45] encompasses
whether decision-making is controlled by the doctor, the
patient, or both. It contains five statements on the extent
of patients’ preferred participation in decision-making,
ranging from an autonomous treatment decision to
complete physician responsibility for the decision.
Within the questionnaire, a rank order of five statements
on the preferred level of participation needs to be indi-
cated. Patients can be categorized into three groups of
active involvement (A and B), passive role (D and E) and
collaborative role (C).Information and supportive care needs and use of
psychosocial support
Questions were developed for this study capturing infor-
mation needs, sources of information and satisfaction
with the information obtained as well as needs for psy-
chosocial support. Use of psychosocial support is
assessed through questions covering the type of support
offers used, satisfaction with the support, basic attitudes
toward psychotherapeutic support, medical referrals and
recommendations as well as reasons for non-use of psy-
chosocial support.Statistical methods
Power calculation
The required sample size was calculated based on the
literature-based 4-week prevalence rates of mental disor-
ders in different strata of cancer patients determined
from an expected prevalence of 30%. A sample size of
2,400 interviews is required to reduce the standard error
of the global prevalence estimate to 1%. To reach 2,400
interviews, 3400 patients needed to be screened by use
of the PHQ-9. Following the sample size calculation it
was determined that each of the five centers had to
enroll approximately 720 patients: 40% each in the
inpatient acute and outpatient care and 20% in rehabili-
tation clinics.
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We use a proportional stratified random sample based
on the nationwide incidence of all cancer diagnoses in
Germany [46]. In this form of stratified random selec-
tion, each stratum is represented in the sample in the
same proportion as in the population. Thus, this form of
stratification allows estimates of mental comorbidity for
all major tumor entities and individual care settings.
Table 2 shows the cancer incidence rates in Germany,
which are the basis for the proportional stratified ran-
dom sample.
Statistical analyses
Potential selection processes will be analyzed by compar-
isons of responders and non-responders on the basis of
demographic and clinical data.
Estimates of the prevalence of mental comorbidity in
the target populations are established on the basis of
observed prevalence rates. Two kinds of estimates will
be reported:
1) Raw (unadjusted) proportions as observed in the
total sample or in strata, to allow comparisons with
other data sources,
2) Estimates resulting from fitting a predictive
hierarchal model to the data that takes into account
the design settings as fixed effects and cluster
structures as random effects, to allow reliable
projections of comorbidity frequencies to
defined health care catchment areas or to





1. prostate 58000 25.4
2. breast 0 -
3. colon/rectum 37000 16.2
4. lung 33000 14.3
5. bladder 21435 9.3
6. female genital organs 0 -
7. hematological malignancies 12650 5.5
8. stomach/esophagus 14900 6.5
9. kidney/urinary tract 10750 4.7
10. malignant melanoma 6500 2.8
11. head and neck 10600 4.6
12. pancreas 6300 2.7
12. thyroid 1500 0.7
12. other 17865 5.6For projections, the estimated prevalence rates will be
extrapolated to the target population by using external
or study-specific weight factors. The oversampling of
patients for the interviews with high depression scores
on the PHQ-9 will be taken into account by a corre-
sponding weighting of the individual prevalence rates as
it has been carried out in similar epidemiological studies
[21,47].
Discussion
Primary purpose of this epidemiological multi-center
study was to detect the 4-weeks-, 12-months-, and
lifetime-prevalence rates of comorbid mental disorders
according to the ICD/DSM in cancer patients. We aim
to enroll a representative sample of patients in terms of
tumor entities and cancer care facilities. On the basis of
epidemiological data on the prevalence of mental disorders
and distress, the needs and demands for the type and
extent of psychosocial support offers can be estimated.
This study was methodologically strong relative to many
studies previously conducted. Our study used a cancer-
incidence-based recruitment strategy for both genders and
a multi-methodological approach including a computer-
based structured clinical interview for the assessment of
mental disorders including adjustment disorder as well as
validated questionnaires for the assessment of subjective
emotional distress and supportive care needs. Our targeted
sample size is larger than those of earlier studies in cancer
patients which allow a variety of subgroup analyses strati-
fied by important risk factors such as cancer progress






n % n %
0 - 58000 13.3
57000 27.8 57000 13.1
36000 17.5 73000 16.7
13200 6.4 46200 10.6
7415 3.6 28750 6.6
27560 13.4 27560 6.3
11350 5.5 24000 5.5
8850 4.3 23750 5.4
6500 3.2 17250 4.0
8400 4.1 14900 3.4
3200 1.6 13800 3.2
6600 3.2 12900 3.0
3500 1.7 5000 1.2
16425 8.0 34390 7.7
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of variability into regard in order to allow reliable pro-
jections for cancer comorbidities that have to be faced in
Germany over the next years.
In summary, our study will provide a large data set
offering detailed and valid information about the specific
mental comorbidities, problems and emotional distress
among cancer survivors with various tumor entities and
disease states. The data further will provide information
about specific demographic, functional, cancer- and
treatment-related risk factors for mental comorbidity
and psychosocial distress, specific supportive care needs
and use of psychosocial support offers.
Thus, epidemiological data provide an important basis
for the implementation of both information and psycho-
social support offers in different health care settings.
The identification of predictors for psychosocial support
needs in cancer patients allow an early and specific as-
signment and referral of those patients to adequate psy-
chosocial support offers. Medical health care will be
improved by the prevention of chronification of mental
disorders and the enhancement of compliance, treat-
ment satisfaction, quality of life and communication be-
tween the cancer patient and the health care team.
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